John P. Schmid bought stock once, on Aug 10, 2026

John P. Schmid is a seasoned biotechnology executive with over 35 years of experience in financial and senior management, having raised more than $900 million in private and public equity as well as debt financings as a Chief Financial Officer.( He co-founded Trius Therapeutics in 2004, serving as CFO through its IPO and until its sale to Cubist Pharmaceuticals in 2013 for over $700 million, and later was CFO of Auspex Pharmaceuticals from 2013, taking it public in 2014 before its $3.5 billion acquisition by Teva in 2015.( Earlier roles include CFO positions at GeneFormatics and Endonetics (acquired by Medtronic), Associate at Idanta Partners, Vice President at HomeFed Bank, and Financial Analyst at Manufacturers Hanover (now part of J.P. Morgan).( Schmid holds a BA in Economics from Wesleyan University and an MBA from the University of San Diego.(

Currently, John P. Schmid serves as a Director on the board of AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases.( On March 30, 2026, he sold 20,645 shares of ANAB stock for approximately $1.16 million, retaining direct ownership of 31,622 shares.( He also sits on the boards of Design Therapeutics (DSGN), Bright Peak Therapeutics, Xeris Biopharma Holdings (XERS), and Speak, Inc. (as Chairman, which he co-founded in 1989), and has previously served on boards including Poseida Therapeutics and Helix Acquisition Corp. II.(

Written by Perplexity from public sources.